Curcumin,a natural product,has exhibited promising effects in both animal models and clinical trials,interacting with a multitude of factors linked to Inflammatory Bowel Disease(IBD).These factors encompass cytokines,...Curcumin,a natural product,has exhibited promising effects in both animal models and clinical trials,interacting with a multitude of factors linked to Inflammatory Bowel Disease(IBD).These factors encompass cytokines,oxidative stress-associated enzymes,and modulation of the intestinal microbiota.Notably,curcumin has demonstrated therapeutic potential in animal models of colitis,wherein it exerts a negative regulatory influence on pivotal signaling pathways such as PI3/Akt,JAK/STAT,andβ-catenin.Moreover,it inhibits the expression of proinflammatory enzymes and co-stimulatory molecules(including RANKL,ICAM-1,CD205,CD256,TLR4,among others),while curbing immune cell chemotaxis,thereby attenuating the characteristic neutrophil infiltration observed in IBD.Another facet of curcumin’s action involves its modulation of the intestinal microbiota.Notably,the microbiota itself contributes to beneficial biotrans formations of curcumin,thereby enhancing its effectiveness in IBD treatment.On a clinical front,curcumin has demonstrated the ability to induce clinical and/or endoscopic remission without any reported toxic effects.Hence,curcumin warrants consideration as an adjunctive therapy in IBD management.Subsequent clinical investigations should concentrate on meticulously evaluating curcumin’s impact on these precise therapeutic targets.展开更多
基金support of the CNPq(Conselho Nacional de Desenvolvimento Científico e Tecnológico)(435704/2018-4)INCT-Bioanalítica(Instituto Nacional de Ciências e Tecnologia em Bioanalítica)(465389/2014-7)+1 种基金CAPES/RENORBIO/PROAP(Coorde-nação de Aperfeiçoamento de Pessoal de Nível Superior)FAPEAL/PPSUS(Fundação de AmparoàPesquisa do Estado de Alagoas/Programa Pesquisa para o SUS)(60030-00879).
文摘Curcumin,a natural product,has exhibited promising effects in both animal models and clinical trials,interacting with a multitude of factors linked to Inflammatory Bowel Disease(IBD).These factors encompass cytokines,oxidative stress-associated enzymes,and modulation of the intestinal microbiota.Notably,curcumin has demonstrated therapeutic potential in animal models of colitis,wherein it exerts a negative regulatory influence on pivotal signaling pathways such as PI3/Akt,JAK/STAT,andβ-catenin.Moreover,it inhibits the expression of proinflammatory enzymes and co-stimulatory molecules(including RANKL,ICAM-1,CD205,CD256,TLR4,among others),while curbing immune cell chemotaxis,thereby attenuating the characteristic neutrophil infiltration observed in IBD.Another facet of curcumin’s action involves its modulation of the intestinal microbiota.Notably,the microbiota itself contributes to beneficial biotrans formations of curcumin,thereby enhancing its effectiveness in IBD treatment.On a clinical front,curcumin has demonstrated the ability to induce clinical and/or endoscopic remission without any reported toxic effects.Hence,curcumin warrants consideration as an adjunctive therapy in IBD management.Subsequent clinical investigations should concentrate on meticulously evaluating curcumin’s impact on these precise therapeutic targets.
